Beddow Capital Management Inc. Sells 62,275 Shares of Pfizer Inc. $PFE

Beddow Capital Management Inc. cut its position in shares of Pfizer Inc. (NYSE:PFE) by 64.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,770 shares of the biopharmaceutical company’s stock after selling 62,275 shares during the quarter. Beddow Capital Management Inc.’s holdings in Pfizer were worth $886,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Pitcairn Co. raised its position in Pfizer by 27.9% in the 3rd quarter. Pitcairn Co. now owns 68,827 shares of the biopharmaceutical company’s stock valued at $1,754,000 after purchasing an additional 15,013 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in Pfizer by 0.9% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 72,857 shares of the biopharmaceutical company’s stock worth $1,856,000 after buying an additional 676 shares in the last quarter. Integrated Quantitative Investments LLC bought a new stake in Pfizer during the 3rd quarter worth about $310,000. Winch Advisory Services LLC increased its position in Pfizer by 3.3% in the 3rd quarter. Winch Advisory Services LLC now owns 18,080 shares of the biopharmaceutical company’s stock valued at $461,000 after acquiring an additional 579 shares in the last quarter. Finally, Advisory Alpha LLC raised its stake in shares of Pfizer by 10.8% in the third quarter. Advisory Alpha LLC now owns 39,668 shares of the biopharmaceutical company’s stock worth $1,074,000 after acquiring an additional 3,882 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Federal judge approved a settlement awarding Pfizer $29 million related to the SEC’s 2013 insider‑trading case involving SAC Capital, closing a long‑running legal dispute and delivering a modest one‑time cash gain. Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund
• Positive Sentiment: Argus Research upgraded PFE to Buy with a $35 target, highlighting encouraging progress in Pfizer’s GLP‑1 obesity program and its oncology pipeline — a bullish catalyst for longer‑term revenue growth expectations. Argus Turns Bullish on Pfizer (PFE), Highlights GLP-1 and Oncology Pipeline
• Positive Sentiment: Investor writeups note portfolio renewal progress and attractive dividend yield for patient investors, framing Pfizer as a value/dividend play while its pipeline rebuild continues. Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Some outlets note the stock is down modestly since the last earnings release and are asking whether it can rebound — a monitoring signal rather than fresh news. Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
• Neutral Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a partnership update that points to operational/automation improvements but is unlikely to move near‑term revenues. Telescope Innovations Installs Second Self-Driving Lab at Pfizer
• Neutral Sentiment: Valuation pieces note divergence between long‑term return expectations and DCF views, signaling mixed investor opinions on fair value and outlook. A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge
• Negative Sentiment: Analysis highlights structural growth challenges — falling COVID revenues, upcoming patent expirations and pricing/IRA headwinds — that could pressure sales and margins if new launches don’t scale. Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
• Negative Sentiment: Opinion pieces warn of “obesity hype” and potential vaccine policy shocks that could create volatility around expectations for new GLP‑1 products and vaccine revenues. Pfizer: Obesity Hype And Vaccine Policy Shocks

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PFE. Argus upgraded Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research report on Monday. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, Bank of America cut their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $28.05.

Pfizer Stock Performance

PFE opened at $26.63 on Friday. The company has a market capitalization of $151.43 billion, a price-to-earnings ratio of 19.58 and a beta of 0.47. The business’s 50-day moving average price is $26.26 and its two-hundred day moving average price is $25.46. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The firm’s revenue was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.63 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.5%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.